Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.82 |
| ▸ | HPGD | P15428 | 3/20 | 0.82 |
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | BRD4 | O60885 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 1/20 | 0.62 |
| ▸ | ACHE | P22303 | 1/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | DRD3 | P35462 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24162968 | 0.88 | HPGD (0.70) | SMN1; SMN2HPGDLMNAALDH1A1L3MBTL1 | |
| SCHEMBL6848908 | 0.88 | SMN1; SMN2 (0.66) | SMN1; SMN2HPGDLMNAALDH1A1L3MBTL1 | |
| SCHEMBL9543614 | 0.88 | MEN1 (0.67) | SMN1; SMN2HPGDLMNAALDH1A1L3MBTL1 | |
| SCHEMBL10949279 | 0.87 | ALDH1A1 (0.69) | SMN1; SMN2HPGDLMNAALDH1A1MAPK1 | |
| SCHEMBL28859140 | 0.85 | NR1H4 (0.82) | SMN1; SMN2HPGDLMNAALDH1A1L3MBTL1 | |
| SCHEMBL7323385 | 0.85 | SMN1; SMN2 (0.62) | SMN1; SMN2HPGDLMNAALDH1A1L3MBTL1 | |
| SCHEMBL2926787 | 0.84 | ALDH1A1 (0.78) | SMN1; SMN2HPGDLMNAALDH1A1L3MBTL1 | |
| SCHEMBL13947134 | 0.83 | L3MBTL1 (0.70) | SMN1; SMN2HPGDLMNAALDH1A1L3MBTL1 | |
| SCHEMBL4738279 | 0.82 | DUSP3 (0.71) | SMN1; SMN2HPGDLMNAALDH1A1L3MBTL1 | |
| SCHEMBL30829417 | 0.82 | L3MBTL1 (0.68) | SMN1; SMN2HPGDLMNAALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013061105-A2 | GLYCOGEN PHOSPHORYLASE INHIBITORS | DEBRECENI EGYETEM (HU) | 2013-05-02 | — | — | WO | disclosed |
| CN-101087793-B | Novel substituted thiophenepyrimidinone derivatives as inhibitors of 17beta-hydroxysteroid dehydrogenase | SOLVAY PHARM BV | 2011-09-07 | — | — | CN | disclosed |
| EP-1635839-B1 | BENZO[4,5]THIENO[2,3-D]PYRIMIDIN-4-ONES AND THEIR USE IN THERAPY | ABBOTT HEALTHCARE PRODUCTS BV (NL) | 2010-09-01 | — | — | EP | disclosed |
| EP-1828197-B1 | NOVEL SUBSTITUTED THIOPHENEPYRIMIDINONE DERIVATIVES AS INHIBITORS OF 17ß-HYDROXYSTEROID DEHYDROGENASE | SOLVAY PHARM GMBH (DE) | 2009-05-13 | — | — | EP | disclosed |
| US-7524853-B2 | Compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2009-04-28 | — | — | US | disclosed |
| US-7465739-B2 | Compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-12-16 | — | — | US | disclosed |
| CN-101087793-A | Novel substituted thiophenepyrimidinone derivatives as inhibitors of 17beta-hydroxysteroid dehydrogenase | SOLVAY PHARM BV (DE) | 2007-12-12 | — | — | CN | disclosed |
| EP-1828197-A1 | NOVEL SUBSTITUTED THIOPHENEPYRIMIDINONE DERIVATIVES AS INHIBITORS OF 17ß-HYDROXYSTEROID DEHYDROGENASE | Solvay Pharmaceuticals GmbH (DE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063615-A1 | NOVEL SUBSTITUTED THIOPHENEPYRIMIDINONE DERIVATIVES AS INHIBITORS OF 17β-HYDROXYSTEROID DEHYDROGENASE | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-06-22 | — | — | WO | disclosed |
| CN-1791412-A | Novel compounds and their use in therapy | SOLVAY PHARM GMBH (NL) | 2006-06-21 | — | — | CN | disclosed |
| US-20050176742-A1 | Novel compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-08-11 | — | — | US | disclosed |
| US-20050038053-A1 | Novel compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-02-17 | — | — | US | disclosed |
| EP-0750607-B1 | 2-(AMINOALKOXY)PHENYLALKYLAMINES WITH ANTIINFLAMMATORY ACTIVITY | KNOLL AG (DE) | 1999-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176742-A1 | Novel compounds and their use in therapy | HSD17B11, HSD17B2, HSD17B1 | SMN1; SMN2 3338/4885HPGD 96/4885LMNA 4510/4885 |
| US-20050038053-A1 | Novel compounds and their use in therapy | HSD17B11, HSD17B2, HSD17B1 | SMN1; SMN2 3338/4885HPGD 96/4885LMNA 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.